Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

Khalil Saleh, MD, Christophe Willekens, MD, Jean Edouard Martin, Myriam Kossai, Nadine Khalifé-Saleh, MD, Véronique Saada, PharmD, Nathalie Auger, Alina Danu, MD, Julien Lazarovici, MD, Alexandra Leary, Suzette Delaloge, Jean Henri Bourhis, MD PhD, Éric Solary, MD PhD, Serge Koscielny, Stephane de Botton, Jean-Baptiste Micol, MD PhD

Blood (2016) 128 (22): 4006.

https://doi.org/10.1182/blood.V128.22.4006.4006

Published: 2016

Journal Articles

BEAM or BeEAM High-Dose Chemotherapy Followed By ASCT: A Single Center Comparative Analysis of Toxicity

Vincent Ribrag, MD, Khalil Saleh, MD, Alina Danu, MD, Serge Koscielny, Sylvain Pilorge, MD, Cristina castilla-Lorente, MD, David Ghez, Ph DMD, Julien Lazarovici, MD, Jean-Marie Michot, MD, Valerie Lapierre, PhD MD, Kamelia Alexandrova, Julia Arfi-Rouche, MD, Jean-Henri Bourhis, MD PhD

Blood (2016) 128 (22): 4648.

https://doi.org/10.1182/blood.V128.22.4648.4648

Published: 2016

Journal Articles

Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation

Christophe Willekens, MD, Angelo Paci, Serge Koscielny, Alice Marceau, Jean-Baptiste Micol, MD, Sophie Broutin, Cyril Quivoron, Véronique Saada, Vianney Poinsignon, Franck Griscelli, Vincent Ribrag, MD, Cristina Castilla-Llorente, Claude Preudhomme, Virginie Lacronique-Penard, Stéphane De Botton

Blood (2015) 126 (23): 3833.

https://doi.org/10.1182/blood.V126.23.3833.3833

Published: 2015

Journal Articles

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Blood (2015) 125 (23): 3618–3626.

https://doi.org/10.1182/blood-2015-01-620781

Published: 2015

Includes: Supplemental data

Journal Articles

Addition of Rituximab Improves Outcome of HIV Negative Patients with Burkitt Lymphoma Treated with the Lmba Protocol: Results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 Protocol. (IGR sponsored LMBA02, NCT00180882)

Vincent Ribrag, MD, Serge Koscielny, ph.D., Krimo Bouabdallah, Service, d'hématologie, clinique, et, de, thérapie, cellulaire, Gilles Salles, MD, Olivier Casasnovas, Christian Recher, MD, Remy Gressin, MD, Jérome Cornillon, M.D., Raoul Herbrecht, MD, Sylviane Iacobelli, Jacques Bosq, M.D., Bertrand Coiffier, MD, PhD

Blood (2012) 120 (21): 685.

https://doi.org/10.1182/blood.V120.21.685.685

Published: 2012

Journal Articles

Improved Survival for 149 First-Line Multiple Myeloma (MM) Patients (pts) Treated by Tandem Autologous (Auto)/Allogeneic (Allo) Stem Cell Transplantation (SCT) : Retrospective Study of the Société Française de Greffe de Moelle Thérapie Cellulaire (SFGM-TC).

Claire Fabre, Serge Koscielny, Jean-Luc Harousseau, Mohamad Mohty, Didier Blaise, Noël Milpied, Bernard Rio, Mauricette Michallet, Thierry Facon, Jean-Paul Vernant, Agnès Buzyn, Gérard Socié, Jean-Yves Cahn, Natacha Maillard, Jacques-Olivier Bay, Jean-Henri Bourhis

Blood (2009) 114 (22): 1188.

https://doi.org/10.1182/blood.V114.22.1188.1188

Published: 2009

Journal Articles

Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis

Vincent Ribrag, Serge Koscielny, Olivier Casasnovas, Cecile Cazeneuve, Pauline Brice, Franck Morschhauser, Jean Gabarre, Aspasia Stamatoullas, Gilbert Lenoir, Gilles Salles

Blood (2009) 113 (14): 3307–3313.

https://doi.org/10.1182/blood-2008-03-148874

Published: 2009

Journal Articles

Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF] and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with Non-Hodgkin Lymphoma.

Jean Abou Yared, MD, Theodore Girinsky, MD, Serge Koscielny, PhD, Vincent Ribrag, MD, Patrice Carde, MD, Suzanna Ceapa, MD, Christophe Ferme, MD

Blood (2008) 112 (11): 1768.

https://doi.org/10.1182/blood.V112.11.1768.1768

Published: 2008

Journal Articles

The JAK2 617V > F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

Sabrina Dupont, Aline Massé, Chloé James, Irène Teyssandier, Yann Lécluse, Frédéric Larbret, Valérie Ugo, Patrick Saulnier, Serge Koscielny, Jean Pierre Le Couédic, Nicole Casadevall, William Vainchenker, François Delhommeau

Blood (2007) 110 (3): 1013–1021.

https://doi.org/10.1182/blood-2006-10-054940

Published: 2007

Includes: Supplemental data

Journal Articles

Implication of BMP7 in Human Mantle Cell Lymphoma (MCL) Secondary Drug Resistance.

Valerie Camara-Clayette, PhD, Serge Koscielny, PhD, Thierry Lamy, MD, PhD, Thierry Fest, MD, Marc Bernard, MD, Vincent Ribrag, MD

Blood (2006) 108 (11): 2589.

https://doi.org/10.1182/blood.V108.11.2589.2589

Published: 2006

Journal Articles

JNK Pathway Is Constitutively Activated and Is Required for Survival in Human Mantle-Cell Lymphoma Fresh Cells and Cell-Lines.

Valerie Camara-Clayette, PhD, William Vainchenker, MD, phD, Serge Koscielny, phD, Olivier Hermine, MD, phD, Vincent Ribrag, MD

Blood (2006) 108 (11): 4602.

https://doi.org/10.1182/blood.V108.11.4602.4602

Published: 2006

Journal Articles

Pharmacogenetic Study in Hodgkin’s Lymphomas, Impact of UGT1A1 on Prognosis.

Vincent Ribrag, MD, Serge Koscielny, phD, Olivier Casasnovas, MD, Cecile Cazeneuve, MD, phD, Pauline Brice, MD, Franck Morschhauser, MD, Jean Gabarre, MD, Marine Divine, MD, Laurent Voillat, MD, Apasia Stamatoullas, MD, Gilbert Lenoir, phD, Gilles Andre Salles, MD, phD

Blood (2006) 108 (11): 2266.

https://doi.org/10.1182/blood.V108.11.2266.2266

Published: 2006

Journal Articles

Long Term Follow-Up Shows No Clinical Benefit for CD34 + Selection of Autologous Transplants Following Myeloablative Therapy in Patients with Newly Diagnosed Myeloma : An EBMT Phase III Randomized Study.

Jean-Henri Bourhis, MD, Yasmina Bouko, MD, Serge Koscielny, PhD, Hildegard Greinix, MD, Gunter Derigs, MD, Gilles Salles, MD, Walter Feremans, MD, Marleen Bakkus, PhD, Jane Apperley, MD, Diana Samson, MD, Bo Bjorkstrand, MD, Dietger Niederwieser, MD, Gosta Gahrton, MD, Jose-Luis Pico, MD, Hartmut Goldschmidt, MD

Blood (2004) 104 (11): 921.

https://doi.org/10.1182/blood.V104.11.921.921

Published: 2004

NARROW

Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

BEAM or BeEAM High-Dose Chemotherapy Followed By ASCT: A Single Center Comparative Analysis of Toxicity

Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Addition of Rituximab Improves Outcome of HIV Negative Patients with Burkitt Lymphoma Treated with the Lmba Protocol: Results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 Protocol. (IGR sponsored LMBA02, NCT00180882)

Improved Survival for 149 First-Line Multiple Myeloma (MM) Patients (pts) Treated by Tandem Autologous (Auto)/Allogeneic (Allo) Stem Cell Transplantation (SCT) : Retrospective Study of the Société Française de Greffe de Moelle Thérapie Cellulaire (SFGM-TC).

Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis

Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF] and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with Non-Hodgkin Lymphoma.

The JAK2 617V > F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

Implication of BMP7 in Human Mantle Cell Lymphoma (MCL) Secondary Drug Resistance.

JNK Pathway Is Constitutively Activated and Is Required for Survival in Human Mantle-Cell Lymphoma Fresh Cells and Cell-Lines.

Pharmacogenetic Study in Hodgkin’s Lymphomas, Impact of UGT1A1 on Prognosis.

Long Term Follow-Up Shows No Clinical Benefit for CD34 + Selection of Autologous Transplants Following Myeloablative Therapy in Patients with Newly Diagnosed Myeloma : An EBMT Phase III Randomized Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only